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The following additional instruments were used in the in-
cluded clinical studies: Memorial Pain Assessment Card, Beck
Depression Inventory, Beck Anxiety Inventory, Short Form McGill
Pain Questionnaire, Edmonton Classification System for Cancer
Pain, Drowsiness Assessment, Mini Mental State Examination
(Folstein Mental State Examination), Center for Epidemiological
Studies Depression Scale (CES-D), John Henryism Active Coping
Scale (JHACS), Barriers Questionnaire (BQ-II), European Organisa-
tion for Research and Treatment of Cancer Quality of Life Ques-
tionnaire Core 30 (EORTC QLQ-C30), and Pain Management
Index (PMI) .
Altogether, assessment of BTP was included in 47 of the 51 pub-
lications of the present review: 21 clinical studies and 26 of the
other publications (reviews, recommendations, expert opinions,
etc.). In addition to the assessment tools used in the clinical stud-
ies, the following instruments were mentioned: VAS for pain inten-
sity, descriptive pain intensity scales (verbal pain rating scales),
FACES, McGill–Melzack Pain Questionnaire, pain diary, Pain
Assessment and Documentation Tool (the US National Pain Educa-
tion Council), Neuropathic Pain Scale, Edmonton Symptom Assess-
ment Scale (ESAS), and Memorial Pain Assessment Scale.
Some of the published reviews and recommendations also
listed specific domains and items to include in the assessment of
BTP, without presenting specific tools. The most detailed recom-
mendations are presented in Supplementary Table 3. The three sets
of recommendations were constructed by expert groups [2,9,27],
and all of them include the domains intensity, temporal factors
(frequency, onset, duration), localisation, pain quality, treatment-
related factors (exacerbating and relieving factors, treatment and
response to treatment), and interference (with activities of daily
living and quality of life). In addition, two of the recommendations
include the relationship of BTP to the chronic (baseline) pain (the
same or different).
3.5. Classification of breakthrough pain
Forty-two of the 51 included papers presented one or more
ways of classifying BTP. Thirty-one classified BTP according to
pathophysiology: somatic, visceral, and neuropathic (Table 1).
Ten papers also included a fourth category, mixed, and Caraceni
and co-workers [3] also included psychogenic mechanism. Some
authors used the common denominator nociceptive for somatic
and visceral pain [2,3,37]. Mercadante and Arcuri [26] distin-
guished between superficial and deep somatic pain, and Walsh
used the three pathophysiological entities neuropathic, visceral,
and musculoskeletal pain [44]. One paper presented a classification
system based on common clinical presentations, encompassing
visceral, neuropathic and bone pain [41]. Svendsen and co-workers
[42] classified non-volitional BTP (incident pain) according to path-
ophysiological mechanism: distension of hollow viscera, ischae-
mia, and possibly metabolic causes.
Twenty-one papers classified BTP according to etiology or
cause: caused directly by the cancer, caused indirectly by the can-
cer, caused by cancer treatment, or unrelated to the cancer disease
(other), i.e. caused by concurrent illness, or unknown/uncertain
(Table 1).
Thirty-seven papers classified BTP according to type or subtype.
Most authors agree on three subtypes: Incident pain, spontaneous
or idiopathic pain, and end-of-dose failure (Table 1). Mixed BTP
may be included as a fourth subtype [17].
End-of-dose failure was also called end-of-dose subtype [33],
end-of-dose pain [22], or related to analgesic regimen or the timing
of the analgesic regimen [34,42,45]. A few authors defined this
pain as the true BTP (inadequate analgesia) [13,23]. One article
specifically mentioned regurgitation of medication as end-of-dose
pain [26]. The opposite view was presented by Simmonds [40] and
Davies et al. [9], who did not wish to include end-of-dose failure in
breakthrough pain; their argument was that the patient does not
have controlled background pain in this situation.
Some authors listed crescendo pain as a separate entity of BTP
[2,30], while Patt and Ellison clearly distinguished BTP from cre-
scendo pain [32].
The subtypes may be defined according to precipitating factors
or predictability. Spontaneous or idiopathic BTP is stimulus-inde-
Text box 1. Breakthrough pain assessment algorithm. (Courtesy of Russell K.
Portenoy and by permission of Oxford University Press [53].)
Table 1
Classification of breakthrough pain: areas of high and low degree of consensus.
Area Summary of consensus points
Term to be used Breakthrough pain
Etiology Caused directly by the cancer
Caused indirectly by the cancer








Type or subtype Incident pain (precipitated)
Volitional (predictable)




Area Main points of disagreement
Definition Is opioid treatment a prerequisite for diagnosing BTP?
Is controlled baseline pain a prerequisite for
diagnosing BTP, and how should controlled baseline
pain be defined?
Should end-of-dose failure be included in BTP?
Formal classification
system
(No formal classification system exists)
D.F. Haugen et al. / PAIN
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0–10); (e) ‘‘Relations with other people’’ – 6 (range 0–10); (f)
‘‘Sleep’’ – 4 (range 0–10); and (g) ‘‘Enjoyment of life’’ – 5.5 (range
0–10).
Most (76%) patients could identify an intervention that usually
improved the breakthrough pain, although another 12% patients
could identify an intervention that sometimes improved the break-
through pain. In other words, 12% patients had found nothing that
relieved their breakthrough pain. The interventions that were suc-
cessful were pharmacological in 132 patients, non-pharmacologi-
cal in 95 patients, a combination of pharmacological and non-
pharmacological in 51 patients, and unspecified in four patients
(totals include interventions that usually and sometimes improved
the breakthrough pain).
Ninety-three patients with isolated spontaneous-type break-
through pain could identify an intervention that usually improved
the breakthrough pain; the intervention was non-pharmacological
in 23 (25%) patients, pharmacological in 58 (62%) patients, a com-
bination of non-pharmacological and pharmacological in 11 (12%)
patients, and not stated in 1 (1%) patient. Similarly, 115 patients
with isolated incident-type breakthrough pain could identify an
intervention that usually improved the breakthrough pain; the
intervention was non-pharmacological in 45 (39%) patients, phar-
macological in 47 (41%) patients, and a combination of non-
pharmacological and pharmacological in 23 (20%) patients.
All patients were using opioid analgesics as rescue medication/
‘‘breakthrough medication’’ (Table 2), whilst 90 (28%) patients
Q1. Do you have pain related to your cancer?
Yes / No
If no, do not proceed with remainder of questionnaire
Q2. Is the pain present most of the time*, or would be present if not taking painkillers? 
(* pain present for ≥12 hr/day during the last week) 
Yes / No
If no, do not proceed with remainder of questionnaire
Q3. Is the pain well controlled for most of the time*?
(* pain rated as ‘none’ or ‘mild’ but not as ‘moderate’ or ‘severe’,    for    ≥12 hr/day during the last 
week) 
Yes / No
If no, do not proceed with remainder of questionnaire
Q4. Do you have short - lived exacerbations of the pain (‘breakthrough pain’)? 
Yes / No
If no, do not proceed with remainder of questionnaire
Q5. Are you taking a strong painkiller* for the constant pain (‘background pain’)? 
(* e.g. morphine, fentanyl, hydromorphone, methadone, oxycodone) 
Yes / No
If no, do not proceed with remainder of questionnaire
Fig. 1. Diagnostic algorithm used to identify patients with breakthrough pain (adapted from Davies et al., 2009).
Table 1
ECOG performance status and cancer diagnosis of subjects.
ECOG performance status Number of patients (n = 320)
ECOG 0 5 (1.5%)
ECOG 1 93 (29.0%)
ECOG 2 107 (33.5%)
ECOG 3 101 (31.5%)
ECOG 4 12 (4.0%)
Not stated 2 (0.5%)
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Algorithm/ Positive% a% b% a%+%b%
Negative% c% d% c%+%d%


























































‘None’% 9% 9%(100%)% 0%
‘Mild’% 60% 50%(83%)% 10%(17%)%
‘Moderate’% 53% 27%(51%)% 26%(49%)%








































































































































































3. Experts!rated!the!quality/character!and!associated-features!of!BTCP!as!relevant.!In!the!patient!interviews!pain!was!most!often!characterised!in!terms!of!severity.!We!considered!quality!and!associated!features!to!be!of!limited!clinical!value!due!to!their!inability!to!discriminate!underlying!pathophysiology,!and!their!wide!variability![213].!4. The!onset-of-BTCP-did!reach!meaningful!consensus!in!the!expert!survey!however,!was!rated!less!relevant!than!duration!and!frequency!of!BTCP.!The!time!between!onset!and!peak!intensity!was!difficult!for!patients!to!calculate!and!varied!significantly!in!the!literature.!Clinically,!if!duration!of!the!episode!is!known,!speed!of!onset!of!pain!is!of!limited!value!in!determining!management!options!and!was!thus!not!included.!5. The!meaning-of-BTCP!for!the!patient!was!a!major!theme!in!the!patient!interviews!associated!with!fear!of!underlying!cancer!progression,!and!fear!of!dying.!It!was!decided,!after!lengthy!discussion,!that!despite!the!importance!of!this!item!in!overall!pain!assessment!and!management,!it!reflected!too!many!different!underlying!constructs!to!have!meaningful!value!in!the!measurement!of!BTCP!specifically.!!6. The!history-of-BTCP!included!the!items!‘time!of!last!BTCP’!and!‘date!BTCP!started’.!The!experts!rated!these!domains!as!less!relevant!than!others!and!information!generated!was!unlikely!to!alter!the!current!clinical!management!of!BTCP.!
5.2.3.2 Questions/
The!following!items!were!included!and!formulated!into!questions!by!the!researchers.!The!aim!of!each!question!was!to!have!as!few!words!as!possible!with!no!ambiguity.!Clarity!and!simplicity!were!considered!essential.!1. Location!of!BTCP!2. Exacerbating!and!relieving!factors!were!considered!highly!relevant!by!both!expert!and!patient!sources.!3. Intensity.!Worst-pain-intensity!was!rated!highly!by!experts!and!featured!significantly!during!patient!interviews!and!was!therefore!included.!However!clinically!it!was!necessary!to!know!whether!the!‘worst!intensity’!represented!
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RMH1% STC2% RSCH3% RMH% STC% RSCH%
Died/ 1% 2% 2% 6% 3% 3%
Unwell/ 4% 1% 2% 5% 5% 2%
Lost/to/follow/up/ 1% 3% 1% 4% 5% 3%
Withdrew/ 2% % % 2% % %












































































































































1! A.216! .302% .391% .146! .237! .086! A.080! .203!
How!long!does!a!typical!BTCP!episode!
last?!
A.216! 1! 0.072! .062! .095! .125! A237! .428% A.003!
How!severe!is!your!worst!episode!of!
BTCP?!!
.302% .072! 1! .623% .461% .579% A.161! .123! A.191!
How!severe!is!a!typical!episode!of!
BTCP?!
.391! .062! .623% 1! .404% .614% A054! .064! .239!
How!much!does!the!BTCP!distress!
you?!
.146! .095! .461% .404% 1! .615! .054! .228! .334!
How!much!does!the!BTCP!stop!you!
from!living!a!normal!life?!
.237! .125! .579% .537% .615% 1! .166! .124! .254!
How!effective!is!the!painkiller!that!you!
usually!take!for!your!BTCP?!
.086! .237! .161! .108! .054! .166! 1! .293% .026!
How!long!does!the!painkiller!for!your!
BTCP!take!to!have!a!meaningful!effect?!
A.08! .428% .123! .064! .228! .124! .293% 1! .085!
How!much!do!the!side!effects!from!
your!BTCP!painkillers!bother!you?!






Factor' Eigenvalues1' %'of'variance2' Cumulative'variance'%'
1' 3.026' 33.618' 33.618'
2' 1.658' 18.426' 52.044'
3' .997' 11.073' 63.117'
4' .891' 9.902' 73.019'
5' .658' 7.310' 80.330'
6' .606' 6.732' 87.061'
7' .486' 5.400' 92.462'
8' .354' 3.937' 96.399'






































































Total!BAT!score! 43.15! 54.62! 0.000! 41.54! 49.25! 0.005!
BAT!severity!subscale! 30.03! 39.26! 0.000! 29.5! 34.68! 0.019!
BAT!treatment!subscale! 13.12! 15.82! 0.023! 12.04! 14.77! 0.027!
How!often!do!you!get!breakthrough!pain?! 5.07! 6.18! 0.009! 5.43! 5.47! 0.922!
How!long!does!a!typical!episode!of!
breakthrough!pain!last?!
6.03! 6.79! 0.182! 6.07! 6.34! 0.654!
How!severe!is!your!worst!breakthrough!pain?! 7.06! 8.26! 0.003! 7.04! 7.68! 0.135!
How!severe!is!a!typical!breakthrough!pain?! 5.51! 6.39! 0.019! 5.62! 5.86! 0.544!
How!much!does!the!breakthrough!pain!
distress!you?!
5.14! 7.41! 0.000! 5.18! 6.21! 0.095!
How!much!does!the!breakthrough!pain!stop!
you!from!living!a!normal!life?!
5.47! 7.36! 0.002! 4.89! 6.66! 0.005!
How!effective!is!the!painkiller!for!your!
breakthrough!pain!(reversed)?!
2.68! 3.87! 0.022! 1.89! 3.54! 0.002!
How!long!does!the!painkiller!take!to!have!a!
meaningful!effect?!
4.90! 6.02! 0.013! 4.52! 5.58! 0.028!
How!much!do!the!side!effects!from!your!
breakthrough!painkiller!bother!you?!













Total!BAT!score! 42.67! 53! 0.000! 42.83! 48.83! 0.029!
BAT!severity!subscale! 29.98! 37.73! 0.000! 30.10! 34.51! 0.045!
BAT!treatment!subscale! 4.74! 6.19! 0.010! 12.72) 14.52) 0.143)
How!often!do!you!get!breakthrough!pain?! 5.13! 5.90! 0.06! 5.31! 5.52! 0.633!
How!long!does!a!typical!episode!of!breakthrough!pain!
last?!
5.93! 6.77! 0.13! 6.21! 6.29! 0.899!
How!severe!is!your!worst!breakthrough!pain?! 7.18! 7.93! 0.06! 7.21! 7.61! 0.336!
How!severe!is!a!typical!breakthrough!pain?! 5.74! 6.00! 0.473! 5.62! 5.85! 0.566!
How!much!does!the!breakthrough!pain!distress!you?! 5.04! 7.12! 0.000! 5.31! 6.17! 0.161!
How!much!does!the!breakthrough!pain!stop!you!from!
living!a!normal!life?!
5.07! 7.50! 0.000! 5.00! 6.64! 0.009!
How!effective!is!the!painkiller!for!your!breakthrough!
pain!(reversed)?!
2.54! 3.68! 0.022! 2.17! 3.44! 0.016!
How!long!does!the!painkiller!take!to!have!a!
meaningful!effect?!
4.73! 6.00! 0.005! 4.79! 5.48! 0.151!
How!much!do!the!side!effects!from!your!breakthrough!
painkiller!bother!you?!







































































Total!BAT!score! .485& .129! .496& .271! .398& 4.165! .456& .473& .35& .399& .377& .208! .485& .565!
BAT!severity!subscale& .560! .089! .537! .278! .435& 4.077! .456& .481& .348& .451& .466& .311& .54! .632!
BAT!treatment!subscale! 4.008! .134! .092! .105! .071! 4.224! .214! .240! .120! .031! .001! 4.154! .114! .113!
How!often!do!you!get!
breakthrough!pain?!
.344& .201! .354& .216! .295! 4.196! .309& 4.008! .012! .165! .216! .316& .262! .239!
How!long!does!a!typical!episode!
of!breakthrough!pain!last?!
4.052! .066! .088! .142! .089! 4.141! .136! .374& .119! .068! .189! 4.199! .105! .167!
How!severe!is!your!worst!
breakthrough!pain?&
.891& .111! .399+ .157! .476+ 4.065! .346& .266! .233! .210! .127! .396& .448& .427&
How!severe!is!a!typical!
breakthrough!pain?&
.545& .213! .473+ .431+ .559& 4.017! .405& .342& .216! .283! .478& .365& .362& .522!
How!much!does!the!
breakthrough!pain!distress!you?!
.402+ 4.185! .320+ .011! .151! .104! .126! .3! .355& .342& .253! .175! .362& .396&
How!much!does!the!BTCP!stop!
you!from!living!a!normal!life?!
.366+ 4.029! .252! .019! .195! 4.110! .672! .5! .615! .571! .336& 4.01! .48& .636!
How!effective!is!the!painkiller!for!
your!breakthrough!pain?!




4.151! .051! 4.016! 4.037! 4.073.! .156! .103! .031! 4.167! .003! 4.124! 4.08! 4.021! 4.075!
How!much!do!side!effects!from!
your!BTCP!painkiller!bother!you?!

















































Better& 49& 16.98&(18.35)& <0.0001&
Same& 20& 4.5&SD&(10.6)& <0.0001&









Better& 45& 17.87& <0.0001&
Same& 26& 4.96& <0.0001&





























16.98& 4.5& -6.9& 12.48& 17.87& 4.96& -8.0& 12.91&
Severity&subscale&
(max=58)&
12.2& 3.2& -4.5& 9& 12.84& 2.57& -4.0& 10.27&
Treatment&subscale&
(max=30)&
5.02& 1.30& -2.4& 3.72& 5.30& 2.38& -4.0& 2.92&
Frequency& 1.33& 0.4& -0.89& 0.93& 1.59& -0.24& -0.22& 1.83&
Duration& 1.95& 0.30& -1.2& 1.65& 1.90& 0.88& -1.33& 1.02&
Worst&BTP&intensity& 2.3& 0.55& -1.3& 1.75& 2.44& 0.19& -0.11& 2.25&
Typical&BTP&intensity& 2.1& 0.65& -0.6& 1.45& 2.04& 0.27& 0.67& 1.77&
Normal&life& 2.88& 1.0& -2.22& 1.88& 3.00& 0.92& -2.22& 2.08&
Distress& 2.04& 0.32& -1.33& 1.72& 2.24& 0.42& -1.78& 1.82&
Effectiveness1& -0.87& 0.5& 0.67& & -1.05& 0.17& 1.14& &
Meaningful&effect1& 0.51& 1.07& -0.67& & 0.59& 1.04& -1.42& &
















Severity&subscale&(max=58)& -0.53& 14.27& 14.77&
Treatment&subscale&(max=30)& -0.14& 6.14& 6.28&
Worst&BTP&intensity&& 0.14& 2.48& 2.34&
Typical&BTP&intensity& 0.31& 2.13& 1.82&
Effectiveness& -0.68& 1.32& 2&
Normal&life& 0.14& 3.07& 2.93&
Distress& -0.44& 2.64& 3.08&
Duration& 0.17& 2.10& 1.93&
Frequency& -0.17& 1.62& 1.79&
Meaningful&effect1& 0.13& 0.94& 0.81&
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The Alberta Breakthrough Pain Assessment TooldResearch
TO BE COMPLETED BY PHYSICIAN OR NURSE 
Instructions:
1. This module should be completed with the patient due to its complexity.  The patient or clinician can 
answer the questions in writing, but if completed by the patient, it must be done under close supervision 
and help must be immediately available if required.
2. The goal is to have the patient characterize up to three distinct types of breakthrough pain. To do this,
define baseline and breakthrough pain for the patient.  Baseline pain can be defined as “the usual, 
steady pain you always experience.”  Breakthrough pain can be defined as “a brief flare-up of pain.  It 
can be a flare-up of the usual, steady pain you always experience (your baseline pain) OR it can be a 
pain that is different from your baseline pain”.
3. First ask the patient to describe his or her baseline pain, which may include a description of the location, 
severity, quality, or other features of this pain, and complete the table below.   
4. Then ask how many different types of breakthrough pains he/she typically experiences in a 24 hour 
period.  A patient may initially distinguish between breakthrough pains on the basis of any of the 
following variables: location, provocation, quality, etiology, or any other variable the patient feels is 
important.  
5. Ask the patient to identify up to three of his/her most bothersome breakthrough pains, and complete 
the table below; these breakthrough pains will be the ones that are characterized.
6. Please photocopy the subsequent pages of this module to individually characterize each of the patient’s 
three most bothersome breakthrough pains.  Note that a separate Module III should be completed for 
each of the patient’s most bothersome breakthrough pains. 
Description of baseline pain 
Describe your baseline pain.
Descriptions of distinct types of breakthrough pain 
What is your most bothersome 
breakthrough pain? 
What is your second most 
bothersome breakthrough pain? 
What is your third most 
bothersome breakthrough pain? 
Treatment Regimen  Q2. Current breakthrough pain 
medications: list trade name of 
formulations [list generic names for all 
opioid and non-opioid analgesics] 
Route of 
Administration 
Dose prn Schedule 
    
    
    
    
    
TO BE COMPLETED BY PATIENT 
For which breakthrough pain are you completing 
this form?  
Q1.  Relationship to baseline pain  
Is this pain a brief flare up of your baseline pain 
or is it a pain that is different from your baseline 
pain? 
  Brief flare up of baseline pain
  Different from baseline pain 
  Not sure 
Q2.  Last time experienced
(a) When did you last have this breakthrough 
pain? (Please refer to your most recent 
breakthrough pain experience, regardless of 




(b) Beginning at what time, approximately? 
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Q3.  Frequency
(a) Approximately how many times in the past 24 
hours have you had this breakthrough pain? 
(Please include ALL breakthrough pain 
experiences, regardless of whether or not you 
took medication for them.) 
(b) During the past 24 hours is this about the 




Q4.  Intensity of pain at peak
(a) When this breakthrough pain is at its worst, 
how would you rate this pain on a scale from 0 to 
10, with 0 being ‘no pain’ and 10 being ‘worst 
possible pain’? 
(b) How would you rate the intensity of this 





















What does the pain feel like? (check √ all that 
apply)
Other (please describe): 
Q7. Time from onset to peak intensity 
When you are awake, on average, how long does 
it usually take from the time you first feel this 
pain until it is at its worst?
more than 0 and up to 10 minutes 
more than 10 and up to 30 minutes 
more than 30 minutes 
It’s hard to say exactly when it started 
Q5.  Location 
Where do you feel this pain?  (Please shade in 
the entire area in which you experience this 
pain)
RL
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Q8. Time from onset to end of episode 
For those pain episodes that you take 
breakthrough pain medication, how long does it 
usually take from the time you take your 
medication until the pain goes away? 
more than 0 and up to 10 minutes 
more than 10 and up to 30 minutes 
more than 30 minutes 
I am not on any breakthrough pain medication 
Movement in bed 
Standing
Coughing
Having a bowel movement 
Swallowing








Is there anything that triggers this breakthrough 
pain? (check √ all that apply) 
It recurs when I feel my scheduled pain medication   
wearing off
No, nothing in particular triggers this pain 
Unsure
Other (please describe): 
Q10. Predictability 
Can you predict when your breakthrough pain 
will occur? 
I can never predict when it will occur 
I can rarely predict when it will occur 
I can sometimes predict when it will occur 
I can often predict when it will occur 
















Does anything help to relieve or prevent your 
breakthrough pain? (check √ all that apply) 
Touching/rubbing/squeezing painful area 
Use of breakthrough pain medication 
Use of scheduled pain medication 
Unsure
Other (please describe): 
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Q12. Relief from breakthrough pain 
medication
In the past 24 hours, how much relief has your 
breakthrough pain medication provided for this 
breakthrough pain? 
No relief  
Slight relief  
Good relief
Very good relief
Complete relief  
Not applicable: I haven’t taken any breakthrough pain
medication in the past 24 hours (skip questions 13-15) 
Q13. Satisfaction with breakthrough pain
medication
In the past 24 hours, how satisfied have you been 
with how well your breakthrough pain 
medication works for this breakthrough pain? 
Very satisfied
Moderately satisfied  
Slightly satisfied  
Neutral
Slightly dissatisfied  
Moderately dissatisfied
Very dissatisfied
Q14. Onset of pain relief 
In the past 24 hours, on average, how long has it 
taken for your breakthrough pain medication to 
begin to reduce your breakthrough pain? (Fill in 
the blank) 
 ____ minutes 
Q15. Satisfaction with onset of pain relief
In the past 24 hours, how satisfied have you been 
with how fast your pain medication begins to 
reduce your breakthrough pain? 
Very satisfied
Moderately satisfied  
Slightly satisfied  
Neutral
Slightly dissatisfied  
Moderately dissatisfied
Very dissatisfied
TO BE COMPLETED BY PHYSICIAN OR NURSE 
Pain related to the site of active cancer 
Pain related to the whole body or systemic effects of the cancer 
disease process (e.g. muscle spasm or bedsores from debility, pain 
from shingles, etc.) 
Pain related to anticancer treatment (e.g. side effects of 
radiotherapy, chemotherapy, surgery) 
Pain caused by a concurrent disorder (e.g. osteoarthritis) 
Q1. Etiology of breakthrough pain 
(check √ all that apply) 
Unknown or uncertain at this time 
Somatic nociceptive  





Q2. Inferred pathophysiology of 
breakthrough pain (check √ all that 
apply)
Unknown or uncertain at this time 
Note: An administrative manual for the Alberta Breakthrough Pain Assessment Tool serves as a technical 
appendix for users, and is available by contacting the authors. 
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Abstract
Context Breakthrough cancer pain is associated with a high
burden of physical, psychological and social problems in
quantitative studies. Individual experiences of living with
breakthrough pain have not been studied.
Objectives This study aims to explore the individual
experience of living with breakthrough cancer pain using
a qualitative methodology.
Methods In depth semi-structured interviews were con-
ducted in ten patients with breakthrough cancer pain, and a
qualitative content analysis was performed.
Results The overarching themes that emerged were daily
living, communication with health care professionals and
management of breakthrough pain.
Conclusions Recognising the impact of breakthrough pain
and the issues expressed by patients regarding communi-
cation and medication gives the clinician a framework for
assessment and intervention.
Keywords Breakthrough cancer pain . Palliative care . Pain
assessment . Adherence . Cancer . Pain management
Introduction
Breakthrough cancer pain has been defined as “a transient
exacerbation of pain that occurs either spontaneously or in
relation to a specific predictable or unpredictable trigger,
despite relatively stable and adequately controlled back-
ground pain” [1]. Breakthrough pain is common in patients
with cancer pain (40–80%) [2] and is a significant cause of
morbidity in this group of patients [3, 4]. Thus, breakthrough
pain is associated with morbidity per se, other physical
problems (e.g. difficulty mobilising, insomnia), psychologi-
cal problems (e.g. anxiety, depression), and social problems
(e.g. inability to work, social isolation) [3–5].
The aforementioned data are derived exclusively from
quantitative studies (usually questionnaire-based studies)
and represent the combined experiences of living with
breakthrough pain in the population studied. However,
breakthrough cancer pain is a heterogeneous condition, and
breakthrough pain episodes vary both between individuals
and also within individuals (at the same time) [6, 7]. The
aim of this unique study was to explore the individual
experiences of living with breakthrough cancer pain in
patients with cancer using a qualitative methodology.
Methods
Setting and sample
The study was conducted at a large United Kingdom cancer
centre, which consists of two hospital sites. The cancer
centre serves a local population of 1.7 million and assesses
and treats 40,000 patients each year. Referrals are received
from throughout the United Kingdom and overseas, and the
centre provides surgical and oncological management for a
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broad range of cancers at different stages. The inclusion
criteria for the study were: (1) age>18 years; (2) diagnosis
of cancer; (3) diagnosis of breakthrough cancer pain; (4)
ability to provide informed consent; (5) ability to undertake
the study interview. To receive a diagnosis of breakthrough
cancer pain, a patient was required to have controlled
baseline pain (mild or less on a verbal rating scale) with
transient exacerbations of more severe pain over the
preceding week. A diagnostic algorithm was used to
confirm the diagnosis of breakthrough cancer pain [1].
Royal Marsden Hospital’s Committee for Clinical
Research, Imperial College London’s Research and Devel-
opment Group and the Royal Marsden Hospital’s Research
Ethics Committee approved the study. All participants
received a patient information sheet, were given the
opportunity to ask a researcher about the study, were given
24 h to consider entering the study and provided written
consent before entering into the study.
Data collection
An in-depth interview was conducted with each participant
in a private room at a place of their convenience. At the
start of the interview, the researcher defined breakthrough
cancer pain (description of the United Kingdom Associa-
tion of Palliative Medicine definition [1]) and explained
that the purpose of the interview was to find out about the
participant’s experiences of this type of pain. A topic guide
(Table 1), based on a review of the literature and
discussions within a multi-disciplinary palliative care team,
was loosely followed with flexibility in the sequence of
topics according to the participant’s responses. Interview
questions focused on the patients’ descriptions of their
breakthrough pain, the impact it had on their life, meaning
of the breakthrough pain and how they managed the
breakthrough pain. The questions were deliberately open
to enable participants to describe aspects of breakthrough
pain experience important to them, as opposed to a more
structured history-taking approach. The initial interview
was used as a pilot to assess the participant, understanding
and acceptability to the content and sequence of questions.
On the basis of this mock interview, it was decided to begin
by asking participants about their diagnosis and current
treatment to help build a rapport and understanding between
interviewer and interviewee. Information from the pilot also
deemed it more acceptable to begin with open-ended general
questions “Tell me about your breakthrough pain?” to enable
the patient to narrate their most significant thoughts before
questioning for more specific details about the impact on
functioning. The more potentially sensitive questions such as,
“Explain how the pain affects you?” and “Does anything
worry you about your breakthrough pain?”were asked later in
the interview when a rapport had been more firmly estab-
lished. Each interview was audio taped, transcribed verbatim
and reviewed prior to the next interview. In addition, “file
notes” were written immediately after each interview. Re-
cruitment continued until data saturation was reached and no
new themes emerged from the interviews. A purposive
sampling approach was used to try and include a cross-
section of characteristics (gender, age, cancer type).
Opening questions Tell me about your breakthrough pain?
What does your breakthrough pain feel like?
Impact on functioning Can you explain how breakthrough pain has affected you?
What is it like to live with breakthrough pain?
How has breakthrough pain changed your life?
How has breakthrough pain affected your day-to-day activities?
Psychological impact What do you feel about your breakthrough pain?
Explain how it affects you as a person
How does it affect your mood?
Meaning of breakthrough pain What does the pain mean to you?
What do you understand about your breakthrough pain?
Does anything worry you about your breakthrough pain?
Management of breakthrough
pain
How do you manage your breakthrough pain?
What helps you to tolerate the breakthrough pain?
How do you feel about the medications that you take?
Communication of breakthrough
pain
Can you tell me your experience of healthcare professionals listening
to you about your breakthrough pain?
What should healthcare professionals ask you to understand your
breakthrough pain?
Concluding questions What do you hope for in the future regarding your breakthrough pain?
Table 1 Interview topic guide





The principal researcher (KW) repeatedly read through the
transcripts to gain an understanding of the nature of the
interviews. Content analysis methodology was used to
initially organise data [8] and subsequently to identify the
overarching themes [9]: the initial coding of units of text was
performed in the margins of the transcripts; these codes were
amalgamated into categories (of similar meaning), and then
these categories were used to identify overarching themes. A
second researcher reviewed the codes and overarching
themes, and discussion was held between the researchers
until both parties agreed on these outcome measures.
Results
Ten patients were approached to take part in the study; all
the patients agreed to take part in the study, and all the
patients completed the study. The characteristics of the
participants are summarised in Table 2 (i.e. age, gender,
diagnosis). All of the participants talked openly about their
experiences of breakthrough pain (duration of interviews:
30–60 min), and there were a number of common
experiences within this group of patients. The overarching
themes that emerged were interference with daily living,
communication with healthcare professionals and manage-
ment of breakthrough pain.
Interference with daily life
Almost all participants reported that the breakthrough pain
had had a major impact on their activities of daily living.
Moreover, participants were often overwhelmed by the
episodes of breakthrough pain. For example, patient 1
stated that during an episode of breakthrough pain: “It takes
up my whole attention and I am just not able to do anything
else except screaming and wishing it would stop.”
Loss of control
The occurrence of breakthrough pain was associated with a
perception of lack of control over their body. This was
particularly apparent in participants with “spontaneous”
(“idiopathic”) breakthrough pain, i.e. unpredictable epi-
sodes of breakthrough pain. Patient 5 commented “you
reach a point where you don’t know whether you’re going
to collapse from the pain.”
Change of lifestyle
Many participants had changed their lifestyle in order to try
to ameliorate the frequency and/or severity of their
breakthrough pain. Patient 6 summarized these changes
as: “It’s like you’ve had a big accident and you’ve lost your
limbs...and you’ve got to change your lifestyle.” These
comments were echoed by patient 7: “You learn to live
your life differently...I do think that to live in less pain you
have to literally do the things, or not do the things that are
going to cause the pain. And you always feel selfish...you
have to do a lot of soul searching and coming to terms with
what you can and can’t do. Why do things that put you in
pain?”
In some cases, the change in lifestyle had been extreme,
often due to an association between movement and the
onset of pain. For example, patient 1 stated: “I am now sort
of bedbound and I am afraid to move very much...I mean
my whole life is at a halt now.” Similarly, patient 4 stated
that he was unable to continue to work: “I own a restaurant
for the last 36 years...you get up and go there and finding
yourself not able to do it.” However, patient 2 reported a
much lower level of restriction: “I don’t think it has
affected my life really. I still go out with the girls if I want
to on an evening...but I can’t walk too far as sometimes that
can bring the dull aches on.”
It was sometimes difficult for participants to differentiate
the impact of breakthrough pain from the other effects of
the cancer. Patient 8 commented: “I’ve lost my day to day
activities...if you took away the pain, I’d still have the
tiredness...You could say it’s to do with weakness, tiredness
and pain.”
Breakthrough pain was also associated with significant
psychological distress: patient 4 stated: “I feel very
depressed when that (pain) comes on.” Similarly, patient 3
stated: “I think when the pain is not there you can be a lot
more positive and get on with a normal life...whereas when
the pain is there that kind of goes away a bit.”
Pain as a reminder of the cancer
All of the participants had cancer, and all had breakthrough
pain related to the underlying malignant disease. Hence, the
Table 2 Participant characteristics
Pt no. Sex Age ECOG Diagnosis
1 F 59 4 Metastatic colorectal cancer
2 F 53 2 Metastatic ovarian cancer
3 F 32 1 Metastatic breast cancer
4 M 57 3 Metastatic bladder cancer
5 M 60 3 Metastatic rectal cancer
6 M 76 2 Metastatic prostate cancer
7 F 54 2 Metastatic breast cancer
8 M 60 2 Metastatic oesophageal cancer
9 M 67 2 Metastatic lung cancer
10 F 74 4 Metastatic breast cancer




occurrence of breakthrough pain was a reminder of the
presence of cancer (and in many cases the presence of
advanced/incurable cancer). Patient 3 commented: “If you
are feeling pain then you are feeling down and the cancer is
constantly on your mind and it is kind of like more of an
uphill struggle, you feel like you are climbing up a great big
mountain.”
Communication with healthcare professionals
Expressing subjective experiences
Pain is a subjective phenomenon, and the participants often
had difficulty in relating their experiences to health
professionals. For example, patient 8 commented: Pain...
it’s difficult to describe pain...it’s really hard to talk to
someone about the pain of cancer when the only person
who’s suffered it is themselves.” Similarly, patient 1
commented: “What can you understand about anybody
else’s pain, everyone has to go through their own. You can
imagine how bad it is from anybody but it is always
different...it is all terribly subjective.”
Often, participants found it easier to describe their
breakthrough pain in terms of severity (e.g. ‘severe’,
‘excruciating’), emotions (e.g. ‘agony’, ‘horrible feeling’)
or impact (e.g. ‘makes me groan’, ‘causes screaming’),
rather than in terms of traditional pain descriptors (e.g.
‘burning’, ‘stinging’).
Use of language/pain scales
The term “breakthrough pain” was not widely understood
by patients, and some participants expressed difficulty in
differentiating between continuous background pain and
intermittent breakthrough pain. Patient 3 commented: “I
think it’s been difficult to know what breakthrough pain is...
I suppose some of it is around the different definitions...and
getting a shared language between patients and health
professional.”
Patient 6 talked about the difficulty in expressing the
severity of pain using numerical rating scales: “And then
erm to have a system of 1 to 10. It’s alright provided both
patient and doctor know what they are talking about. I
mean what is 1? What is 10... you can go from 1 to 10 as
easy as pie.” Patient 9 also commented on the use of
numerical rating scales: “On this scale, this 1 to 10, I
suppose my version of no pain would be 4.”
Impact of language
Patient 7 described how the words used by a particular
healthcare professional had influenced her perception of the
breakthrough pain: “The doctor said, ‘You’ve all been eaten
away here.’ Now the pain feels like a rat gnawing at you
that couldn’t stop.” She used this image to describe her pain
throughout the interview, and it was clear that the
aforementioned consultation had had a significant/negative
impact on her experience of the pain.
Need to understand pain
All of the participants stated that it was important to receive
a clear understanding of the underlying cause of the
breakthrough pain from healthcare professionals (“If I’ve
got a pain I want to understand why I’ve got a pain
[patient 5]).”
Patient 2 felt that understanding the cause of the
breakthrough pain had alleviated her concerns about the
meaning of the pain: “It is the not knowing, I think that is
always the worst...if it can be explained it is very helpful if
not relieving and reassuring even, to some people.”
Similarly, patient 3 explained that a better understanding
of the pain had led to improvements in the treatment of her
pain: “I didn’t want my pain to go as it was a way for me to
monitor my cancer...I know now that it’s not such a link,
knowing I can be pain free came as a relief.”
Management of breakthrough pain
Conflict regarding medication
Every participant was taking opioid analgesia for their
breakthrough pain, and there were many concerns
expressed about the use of this group of drugs (e.g. not
wanting to mask the pain, morphine as a ‘last resort’, fear
of side-effects, fear of addiction). Indeed, patient 10 stated:
“at the moment I’m still trying to keep as much control of
my life as I can and I don’t want that (morphine) cos I feel
too woozy with it and I don’t want to sit here sort of in a
half silly state, thank you.”
However, the concerns were often tempered by the
acceptance that such medication was often necessary to
manage the breakthrough pain and to maintain a reasonable
quality of life. For example, patient 2 stated: “I mean I
don’t like the idea that I’m on morphine but erm on this
level that I’m on it seems to be pretty good. I am just
grateful there is something extra that I can take quite
honestly... I always make sure I have tablets with me so in
the back of my mind I know I’m covered so I can just do
whatever I want to do.”
Specialist expertise
The participants often stated that their breakthrough pain
had been sub-optimally managed by their regular physi-
cians and had only become well controlled after referral to




the palliative care/pain services. Patient 3 commented that:
“My G.P. (family practitioner) didn’t seem to take me
seriously and it took me a while to get tapped into the pain
team who were the most help. I think it is best managed by
the pain team.”
The participants recognised that treatment needed to be
individualised and commented that the tolerability of the
drug was just as important as the efficacy of the drug.
Patient 7 described her experiences: “You’ve got to go
through a trial to see which one works for you and I’m glad
I did that...if you’re put on the wrong dose to start with and
you’re as sick as I was then you don’t believe the pill’s ever
going to work...so what you want is something that takes
you enough out of pain...but not take you to gaga land.”
Discussion
The information derived from this study demonstrates the
true impact of breakthrough pain on activities of daily
living. Thus, many of the participants had needed to make
changes to their lifestyle, and in some cases, the changes in
lifestyle were profound (e.g. giving up working). Such
lifestyle changes have implications not only for the patient
but also for the patient’s family and the wider society.
However, other participants had needed to make lesser
changes to their lifestyle, which may reflect differences in
breakthrough pain experience and/or breakthrough pain
management. It was evident that lifestyle changes were
associated with feelings of ‘loss of role’ and contributed to
psychological distress associated with breakthrough pain.
It has been recommended that the assessment of patients
with breakthrough pain should include an appraisal of any
interference with activities of daily living [1]. Such
information will help to identify potential strategies to help
the patient cope with their breakthrough pain (e.g. physical
adaptations, social services) [10] and can be used as a
surrogate measure of the efficacy of therapeutic interven-
tions [1].
Communication difficulties were identified as a major
problem and often related to issues around the assessment of
breakthrough pain. Currently, there is no universally accepted
definition of breakthrough pain, and the term is used
inconsistently within clinical practice [1]. Indeed, the term
is frequently/incorrectly used to describe any exacerbation of
pain, rather than an exacerbation of pain in a patient with
well-controlled background pain. Hence, it is not surprising
that some patients were unsure about the meaning of the
term “breakthrough pain”. Furthermore, patients found it
difficult to use conventional pain descriptors and also to use
conventional pain scales (i.e. numerical rating scales).
The successful management of breakthrough pain is
dependent on a thorough assessment of the pain (and
ongoing thorough re-assessment of the pain) [1]. Indeed,
inadequate assessment is recognised as one of the barriers
to good pain control [11, 12]. It is vital that healthcare
professionals ask the “right” questions and equally that
patients are clear about what they are actually being asked.
Moreover, any medical terminology should be appropriately
defined.
Many of the participants highlighted internal conflicts
regarding the use of opioid analgesia. Indeed, in some
cases, participants would rather suffer from the pain than
suffer from the adverse effects of the pain medication.
Concerns about adverse effects of pain medication are a
common reason for non-adherence [7] and thus common
reason for poor pain control [12]. Patients need to be
reassured about the safety of pain medication and regularly
assessed for the presence of adverse effects; patients with
adverse effects should have their treatment reviewed, and
(if necessary) should be referred to specialist services (i.e.
palliative care/pain services). Thus, there are an increasing
number of options for the management of breakthrough
cancer pain (http://www.breakthroughcancerpain.org).
There were a number of limitations to this research
project. This study was conducted in a specialist cancer
centre; therefore, results may not be generalised to other
palliative care populations. However, semi-purposive sam-
pling was used to recruit patients with a variety of
diagnoses and ages to try and access different views. The
sample size was relatively small and provided information
that can only be used to generate further hypotheses. The
cross-sectional nature of the study did not allow for the
examination of changes in breakthrough cancer pain over
time. Finally, none of the participants were familiar with the
term ‘breakthrough cancer pain’ and all had had previous
episodes of uncontrolled, continuous background pain. As a
result, it was often difficult for participants to discuss only
their previous breakthrough pain experience and not
include the episodes when their pain was uncontrolled.
This could mean that many of the themes identified may
also be relevant to cancer pain in general. This highlights an
important issue for all research into breakthrough cancer
pain, and investigators must be aware of participants’
difficulty in separating various aspects of their pain
experience and always define clearly the pain they are
investigating.
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